Literature DB >> 7747420

A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.

M Connors1, J E Crowe, C Y Firestone, B R Murphy, P L Collins.   

Abstract

In previous studies, a mutant (cp-RSV) of the RSV A2 strain derived from 52 serial cold passages in bovine embryonic tissue culture was highly attenuated in seropositive adults and children but caused upper respiratory tract disease in seronegative infants. We investigated the genetic basis for this attenuation phenotype by comparing the complete genomic RNA sequence of this virus with the published sequence of strain A2 as well as with that of its unattenuated wild-type parent (HEK-7) virus. RNA was extracted from virions grown in tissue culture, reverse transcribed, amplified by the polymerase chain reaction (PCR), cloned, and sequenced. Changes from the published A2 wild-type sequence were confirmed on independently derived cDNA clones and by direct sequencing of PCR fragments. The HEK-7 parent virus was then analyzed at these positions by direct sequencing of PCR fragments. Fifteen nucleotide differences between the published A2 wild-type virus and cp-RSV were found. None appeared to involve cis-acting RNA sequences. Of the 15 nucleotide differences, only 1 occurred outside a translational open reading frame (ORF), and 2 which did occur within ORFs were silent at the amino acid level. The remaining 12 nucleotide differences encoded amino acid changes. All 3 of the mutations which were silent at the amino acid level, and 8 of the 12 which resulted in amino acid differences, were also present in the HEK-7 parent virus and therefore were not changes acquired during the cold passages. Thus, the remaining 4 nucleotide differences and the attendant 4 amino acid changes are associated with the attenuation phenotype of the cp-RSV. Two of the changes occur in the F gene and two in the L gene. These results confirm the previously described RSV genomic sequence, provide the first sequence of a live attenuated RSV vaccine strain, provide the first sequence of an RSV strain which has been evaluated in chimpanzees and humans, and indicate that attenuation in humans of a pneumovirus can be associated with a relatively small number of nucleotide and amino acid changes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747420     DOI: 10.1006/viro.1995.1178

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.

Authors:  K Juhasz; S S Whitehead; P T Bui; J M Biggs; J E Crowe; C A Boulanger; P L Collins; B R Murphy
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.

Authors:  S S Whitehead; K Juhasz; C Y Firestone; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.

Authors:  J E Crowe; C Y Firestone; S S Whitehead; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

4.  A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.

Authors:  Steffen Mueller; Charles B Stauft; Raj Kalkeri; Fusataka Koidei; Anna Kushnir; Sybil Tasker; J Robert Coleman
Journal:  Vaccine       Date:  2020-02-24       Impact factor: 3.641

5.  Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro.

Authors:  Stéphane Biacchesi; Brian R Murphy; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.

Authors:  P L Collins; M G Hill; E Camargo; H Grosfeld; R M Chanock; B R Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; Christopher L Parks; Todd S Laughlin; C Kanta Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Authors:  Hoyin Mok; Sujin Lee; Thomas J Utley; Bryan E Shepherd; Vasiliy V Polosukhin; Martha L Collier; Nancy L Davis; Robert E Johnston; James E Crowe
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

10.  Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Authors:  Matthew B Elliott; Karin S Pryharski; Qingzhong Yu; L A Boutilier; N Campeol; K Melville; Todd S Laughlin; C K Gupta; Robert A Lerch; Valerie B Randolph; Natisha A LaPierre; Kristen M Heers Dack; Gerald E Hancock
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.